Advanced Solid Tumor Malignancies
8
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
Lymphocyte Function Testing in Immuno-oncology
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
ATI-2231 in Advanced Solid Tumor Malignancies
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies